New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine

To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy. This was an 18-center, randomized, double-blind, double dummy, parallel study of 593 elderly subjects with...

Full description

Saved in:
Bibliographic Details
Published inNeurology Vol. 64; no. 11; p. 1868
Main Authors Rowan, A J, Ramsay, R E, Collins, J F, Pryor, F, Boardman, K D, Uthman, B M, Spitz, M, Frederick, T, Towne, A, Carter, G S, Marks, W, Felicetta, J, Tomyanovich, M L
Format Journal Article
LanguageEnglish
Published United States 14.06.2005
Subjects
Online AccessGet more information

Cover

Loading…
Abstract To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy. This was an 18-center, randomized, double-blind, double dummy, parallel study of 593 elderly subjects with newly diagnosed seizures. Patients were randomly assigned to one of three treatment groups: GBP 1,500 mg/day, LTG 150 mg/day, CBZ 600 mg/day. The primary outcome measure was retention in trial for 12 months. Mean age was 72 years. The most common etiology was cerebral infarction. Patients had multiple medical conditions and took an average of seven comedications. Mean plasma levels at 6 weeks were as follows: GBP 8.67 +/- 4.83 microg/mL, LTG 2.87 +/- 1.60 microg/mL, CBZ 6.79 +/- 2.92 microg/mL. They remained stable throughout the trial. Early terminations: LTG 44.2%, GBP 51%, CBZ 64.5% (p = 0.0002). Significant paired comparisons: LTG vs CBZ: p < 0.0001; GBP vs CBZ: p = 0.008. Terminations for adverse events: LTG 12.1%, GBP 21.6%, CBZ 31% (p = 0.001). Significant paired comparisons: LTG vs CBZ: p < 0.0001; LTG vs GBP: p = 0.015. There were no significant differences in seizure free rate at 12 months. The main limiting factor in patient retention was adverse drug reactions. Patients taking lamotrigine (LTG) or gabapentin (GBP) did better than those taking carbamazepine. Seizure control was similar among groups. LTG and GBP should be considered as initial therapy for older patients with newly diagnosed seizures.
AbstractList To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy. This was an 18-center, randomized, double-blind, double dummy, parallel study of 593 elderly subjects with newly diagnosed seizures. Patients were randomly assigned to one of three treatment groups: GBP 1,500 mg/day, LTG 150 mg/day, CBZ 600 mg/day. The primary outcome measure was retention in trial for 12 months. Mean age was 72 years. The most common etiology was cerebral infarction. Patients had multiple medical conditions and took an average of seven comedications. Mean plasma levels at 6 weeks were as follows: GBP 8.67 +/- 4.83 microg/mL, LTG 2.87 +/- 1.60 microg/mL, CBZ 6.79 +/- 2.92 microg/mL. They remained stable throughout the trial. Early terminations: LTG 44.2%, GBP 51%, CBZ 64.5% (p = 0.0002). Significant paired comparisons: LTG vs CBZ: p < 0.0001; GBP vs CBZ: p = 0.008. Terminations for adverse events: LTG 12.1%, GBP 21.6%, CBZ 31% (p = 0.001). Significant paired comparisons: LTG vs CBZ: p < 0.0001; LTG vs GBP: p = 0.015. There were no significant differences in seizure free rate at 12 months. The main limiting factor in patient retention was adverse drug reactions. Patients taking lamotrigine (LTG) or gabapentin (GBP) did better than those taking carbamazepine. Seizure control was similar among groups. LTG and GBP should be considered as initial therapy for older patients with newly diagnosed seizures.
Author Ramsay, R E
Spitz, M
Marks, W
Frederick, T
Carter, G S
Boardman, K D
Felicetta, J
Pryor, F
Towne, A
Uthman, B M
Rowan, A J
Collins, J F
Tomyanovich, M L
Author_xml – sequence: 1
  givenname: A J
  surname: Rowan
  fullname: Rowan, A J
  email: aj.rowan@med.va.gov
  organization: VA Medical Center, Bronx, NY 10468, USA. aj.rowan@med.va.gov
– sequence: 2
  givenname: R E
  surname: Ramsay
  fullname: Ramsay, R E
– sequence: 3
  givenname: J F
  surname: Collins
  fullname: Collins, J F
– sequence: 4
  givenname: F
  surname: Pryor
  fullname: Pryor, F
– sequence: 5
  givenname: K D
  surname: Boardman
  fullname: Boardman, K D
– sequence: 6
  givenname: B M
  surname: Uthman
  fullname: Uthman, B M
– sequence: 7
  givenname: M
  surname: Spitz
  fullname: Spitz, M
– sequence: 8
  givenname: T
  surname: Frederick
  fullname: Frederick, T
– sequence: 9
  givenname: A
  surname: Towne
  fullname: Towne, A
– sequence: 10
  givenname: G S
  surname: Carter
  fullname: Carter, G S
– sequence: 11
  givenname: W
  surname: Marks
  fullname: Marks, W
– sequence: 12
  givenname: J
  surname: Felicetta
  fullname: Felicetta, J
– sequence: 13
  givenname: M L
  surname: Tomyanovich
  fullname: Tomyanovich, M L
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15955935$$D View this record in MEDLINE/PubMed
BookMark eNo1j11LwzAYhYMozk3_ggSv15qkzZd3MuYHjHmj6JXjbfJmRNa0tB2y_XoL6rk5N8954EzJaWoSEnLDWc4FF7eM5-_rVc7GcKULU-bKCKbzYnlCLrgUKlOF-JiQad9_jYgU2p6TCZdWSlvIC_K5xm_apB4HusUuwtBFR7GNO2z7wx0F2kHyTR2P6Gk_7P2BNoFuoYIW0xDTnO6gbsbRNiac05GlDroKajiOkoSX5CzArserv56Rt4fl6-IpW708Pi_uV5krSj1kGlgo0TjDSg_GC8O8NBrKyiiNXJsqCBWsktYb6b0OigWLyjruLDrnvZiR619vu69q9Ju2izV0h83_UfEDNnRZWw
CitedBy_id crossref_primary_10_1002_14651858_CD011922_pub4
crossref_primary_10_1016_j_ijge_2012_05_013
crossref_primary_10_1002_epi4_12239
crossref_primary_10_1016_j_archger_2024_105605
crossref_primary_10_1002_phar_1855
crossref_primary_10_1016_S1474_4422_20_30035_1
crossref_primary_10_17749_2077_8333_epi_par_con_2023_135
crossref_primary_10_1016_S0513_5117_08_70129_7
crossref_primary_10_2174_1570159X20666220507020635
crossref_primary_10_1111_epi_13448
crossref_primary_10_1016_j_neurol_2008_10_028
crossref_primary_10_1002_gps_1784
crossref_primary_10_1016_j_yebeh_2007_04_007
crossref_primary_10_3390_w13182539
crossref_primary_10_1017_S1748232106000061
crossref_primary_10_1016_j_heliyon_2024_e26376
crossref_primary_10_1007_s00115_011_3339_y
crossref_primary_10_1016_j_eplepsyres_2024_107496
crossref_primary_10_1016_j_seizure_2010_05_008
crossref_primary_10_1016_j_jamda_2007_11_004
crossref_primary_10_1007_s15202_013_0426_x
crossref_primary_10_1016_j_eplepsyres_2010_02_008
crossref_primary_10_1111_j_1399_5618_2011_00923_x
crossref_primary_10_1111_j_1600_0404_2006_00748_x
crossref_primary_10_1007_s00115_007_2328_7
crossref_primary_10_1016_j_mayocp_2016_11_013
crossref_primary_10_1097_WAD_0000000000000134
crossref_primary_10_1016_j_eplepsyres_2016_09_021
crossref_primary_10_1517_14740338_5_3_401
crossref_primary_10_1016_j_yebeh_2020_107540
crossref_primary_10_1111_epi_13675
crossref_primary_10_1002_phar_2012
crossref_primary_10_1177_2042098613505614
crossref_primary_10_1097_WCO_0000000000001143
crossref_primary_10_1212_CON_0000000000001521
crossref_primary_10_1590_S1676_26492009000200003
crossref_primary_10_1002_14651858_CD011922_pub3
crossref_primary_10_1002_14651858_CD011922_pub2
crossref_primary_10_1016_j_yebeh_2014_04_014
crossref_primary_10_1177_1533317518813551
crossref_primary_10_1007_s12151_007_0045_y
crossref_primary_10_1007_s00115_007_2257_5
crossref_primary_10_1111_j_1755_5949_2011_00251_x
crossref_primary_10_3233_JRS_235001
crossref_primary_10_1016_j_seizure_2018_08_001
crossref_primary_10_1097_FTD_0b013e31824d6a4e
crossref_primary_10_1016_j_yebeh_2010_12_033
crossref_primary_10_1111_j_1528_1167_2008_01447_x
crossref_primary_10_1097_01_wco_0000218239_90711_bd
crossref_primary_10_1002_14651858_CD001031_pub4
crossref_primary_10_1177_0883073807303253
crossref_primary_10_1002_14651858_CD001031_pub3
crossref_primary_10_1111_epi_14519
crossref_primary_10_52667_2712_9179_2021_1_2_46_62
crossref_primary_10_17749_2077_8333_epi_par_con_2022_117
crossref_primary_10_1002_jppr_1135
crossref_primary_10_1016_j_lfs_2018_01_021
crossref_primary_10_3988_jcn_2020_16_4_556
crossref_primary_10_1016_j_seizure_2007_01_004
crossref_primary_10_1016_j_yebeh_2014_03_008
crossref_primary_10_1007_s12612_009_0018_8
crossref_primary_10_1038_nrneurol_2009_74
crossref_primary_10_1111_epi_16366
crossref_primary_10_1212_01_CON_0000368235_64857_cf
crossref_primary_10_7759_cureus_30195
crossref_primary_10_1016_S1474_4422_07_70115_1
crossref_primary_10_1016_j_yebeh_2015_03_027
crossref_primary_10_1136_bcr_2012_006881
crossref_primary_10_1016_j_neurol_2011_10_012
crossref_primary_10_1016_j_seizure_2013_06_005
crossref_primary_10_1097_01_nrl_0000256353_14257_7c
crossref_primary_10_1007_s15005_015_1378_9
crossref_primary_10_1111_j_1528_1167_2007_01128_x
crossref_primary_10_1345_aph_1L305
crossref_primary_10_1016_j_jstrokecerebrovasdis_2014_07_050
crossref_primary_10_1007_s00115_008_2638_4
crossref_primary_10_1177_0091270007313391
crossref_primary_10_1007_s11940_022_00740_5
crossref_primary_10_1111_ane_13312
crossref_primary_10_1007_s40266_018_0562_2
crossref_primary_10_1186_s12883_016_0663_7
crossref_primary_10_1093_ijpp_riae055
crossref_primary_10_1590_0004_282x_anp_2020_0012
crossref_primary_10_1007_s11940_008_0026_9
crossref_primary_10_1016_j_yebeh_2005_05_003
crossref_primary_10_1016_S1634_7072_20_43686_4
crossref_primary_10_1007_s10309_022_00492_x
crossref_primary_10_1007_s11910_016_0696_8
crossref_primary_10_2220_biomedres_38_297
crossref_primary_10_1001_jamaneurol_2018_1935
crossref_primary_10_1007_s10309_014_0385_z
crossref_primary_10_1097_01720610_200702000_00016
crossref_primary_10_4137_CMT_S2165
crossref_primary_10_1016_j_seizure_2015_06_016
crossref_primary_10_1016_j_seizure_2017_04_010
crossref_primary_10_1007_s40266_022_00998_z
crossref_primary_10_1111_j_1535_7511_2007_00198_x
crossref_primary_10_1002_ana_22439
crossref_primary_10_1016_j_eplepsyres_2005_09_031
crossref_primary_10_1021_acs_orglett_9b00655
crossref_primary_10_1007_s11936_013_0236_7
crossref_primary_10_1212_WNL_64_11_1834
crossref_primary_10_2165_00003495_200666130_00004
crossref_primary_10_1017_S0959259808002694
crossref_primary_10_1111_j_1528_1167_2012_03640_x
crossref_primary_10_1016_S1634_7072_21_44998_6
crossref_primary_10_1111_j_1528_1167_2008_01892_x
crossref_primary_10_18231_j_ijn_2022_005
crossref_primary_10_1007_s42451_019_00135_y
crossref_primary_10_1016_j_eplepsyres_2016_08_018
crossref_primary_10_2217_1745509X_3_4_509
crossref_primary_10_1016_S1474_4422_12_70105_9
crossref_primary_10_1016_j_eplepsyres_2005_09_018
crossref_primary_10_2165_00002512_200623110_00002
crossref_primary_10_1016_j_jns_2018_09_026
crossref_primary_10_1017_S1092852900027632
crossref_primary_10_1111_j_1528_1167_2008_01584_x
crossref_primary_10_1016_j_annemergmed_2024_01_033
crossref_primary_10_1111_j_1528_1167_2008_01561_x
crossref_primary_10_1016_j_nrl_2014_08_002
crossref_primary_10_1016_j_eplepsyres_2013_08_009
crossref_primary_10_1016_j_eplepsyres_2005_09_020
crossref_primary_10_1212_WNL_0b013e3182477edc
crossref_primary_10_1016_j_neurobiolaging_2014_06_009
crossref_primary_10_1016_j_yebeh_2024_109913
crossref_primary_10_1016_j_yebeh_2005_11_007
crossref_primary_10_1016_j_ejpb_2014_12_027
crossref_primary_10_1016_j_eplepsyres_2016_08_023
crossref_primary_10_1212_01_wnl_0000261917_83337_db
crossref_primary_10_3389_fneur_2018_00995
crossref_primary_10_1007_s10309_009_0033_1
crossref_primary_10_1007_s12028_007_0042_8
crossref_primary_10_1111_ene_12766
crossref_primary_10_1111_epi_17426
crossref_primary_10_1016_j_yebeh_2019_106724
crossref_primary_10_1111_ane_12162
crossref_primary_10_1007_s10309_022_00491_y
crossref_primary_10_2217_1745509X_1_1_147
crossref_primary_10_3233_JAD_220983
crossref_primary_10_1016_S0246_0378_12_70007_6
crossref_primary_10_1080_14656566_2018_1496237
crossref_primary_10_1111_j_1528_1167_2006_00664_x
crossref_primary_10_1002_14651858_CD011412_pub4
crossref_primary_10_1002_epi4_3
crossref_primary_10_1016_j_yebeh_2008_01_003
crossref_primary_10_1016_j_ncl_2011_07_001
crossref_primary_10_1016_S0211_3449_07_75454_1
crossref_primary_10_1002_14651858_CD011412_pub3
crossref_primary_10_1016_j_yebeh_2007_09_003
crossref_primary_10_1002_14651858_CD011412_pub2
crossref_primary_10_1016_j_yebeh_2009_10_019
crossref_primary_10_2217_ahe_09_88
crossref_primary_10_1007_s10309_014_0383_1
crossref_primary_10_1001_jamaneurol_2021_2249
crossref_primary_10_1016_j_mcna_2018_10_002
crossref_primary_10_1590_0004_282X20140151
crossref_primary_10_1111_j_1600_0404_2008_01018_x
crossref_primary_10_1002_14651858_CD005398_pub3
crossref_primary_10_1111_j_1528_1167_2009_02069_x
crossref_primary_10_3390_ijms241612639
crossref_primary_10_1016_S1474_4422_09_70240_6
crossref_primary_10_3805_eands_15_104
crossref_primary_10_1002_14651858_CD005398_pub4
crossref_primary_10_1212_WNL_0b013e3181d25b34
crossref_primary_10_5698_1535_7511_12_6_225
crossref_primary_10_1016_S0140_6736_06_68477_8
crossref_primary_10_4158_EP12119_OR
crossref_primary_10_1080_14737175_2023_2278487
crossref_primary_10_1016_S0140_6736_07_60460_7
crossref_primary_10_2165_0002512_200926020_00007
crossref_primary_10_1111_epi_13853
crossref_primary_10_1016_S1474_4422_17_30044_3
crossref_primary_10_1517_14656560902772328
crossref_primary_10_4140_TCP_sA_2009_001
crossref_primary_10_1016_j_eplepsyres_2015_02_018
crossref_primary_10_1212_CON_0000000000001104
crossref_primary_10_1007_s10309_024_00733_1
crossref_primary_10_1212_CPJ_0b013e31823d07d1
crossref_primary_10_1016_S1634_7072_12_62057_1
crossref_primary_10_1007_s11940_014_0295_4
crossref_primary_10_1212_WNL_67_12_suppl_4_S3
crossref_primary_10_2176_nmc_ra_2015_0344
crossref_primary_10_3390_ph3092956
crossref_primary_10_1007_s40266_017_0465_7
crossref_primary_10_1002_epi4_12996
crossref_primary_10_1007_s40266_021_00837_7
crossref_primary_10_1016_j_ncl_2015_11_007
crossref_primary_10_1212_WNL_0000000000007010
crossref_primary_10_1111_epi_12074
crossref_primary_10_1111_epi_14010
crossref_primary_10_1177_2042098612455357
crossref_primary_10_1016_j_amjmed_2021_01_038
crossref_primary_10_1111_j_1600_0404_2005_00508_x
crossref_primary_10_5698_1535_7597_18_4_260
crossref_primary_10_1016_j_eplepsyres_2007_04_009
crossref_primary_10_1016_j_nrleng_2014_08_002
crossref_primary_10_1586_14737175_6_11_1609
crossref_primary_10_1016_j_praneu_2011_09_001
crossref_primary_10_1016_j_yebeh_2023_109159
crossref_primary_10_1080_14737175_2017_1243469
crossref_primary_10_1517_17425255_2012_645535
crossref_primary_10_1007_s10309_008_0308_y
crossref_primary_10_35615_epilia_2020_00143
crossref_primary_10_1111_bcp_13653
crossref_primary_10_36150_2499_6564_334
crossref_primary_10_1016_j_yebeh_2008_12_006
crossref_primary_10_3389_fneur_2022_855498
crossref_primary_10_1177_1533317508319433
crossref_primary_10_1016_j_eplepsyres_2006_10_008
crossref_primary_10_1212_WNL_0000000000005755
crossref_primary_10_1016_j_eplepsyres_2017_10_021
crossref_primary_10_1016_j_seizure_2017_05_002
crossref_primary_10_1002_jac5_1123
crossref_primary_10_1007_s12151_007_0059_5
crossref_primary_10_1016_j_seizure_2018_11_013
crossref_primary_10_1111_epi_17516
crossref_primary_10_1007_s13760_012_0070_9
crossref_primary_10_2217_1745509X_2_4_599
crossref_primary_10_1007_s13670_014_0078_5
crossref_primary_10_3805_eands_3_24
crossref_primary_10_1111_j_1600_0404_2010_01440_x
crossref_primary_10_1016_S1474_4422_11_70047_3
crossref_primary_10_1016_j_regg_2009_05_010
crossref_primary_10_1016_j_neuroscience_2014_11_051
crossref_primary_10_1212_01_wnl_0000345667_45642_61
crossref_primary_10_1016_j_eplepsyres_2006_10_011
crossref_primary_10_1212_01_WNL_0000291947_29643_9f
crossref_primary_10_2165_11631540_000000000_00000
crossref_primary_10_1161_STROKEAHA_120_033299
crossref_primary_10_1016_j_regg_2019_02_003
crossref_primary_10_1111_ane_12529
crossref_primary_10_1016_j_ijpharm_2016_01_001
crossref_primary_10_1007_s13760_019_01132_4
crossref_primary_10_1212_CON_0000000000000715
crossref_primary_10_1111_j_1528_1167_2007_01123_x
crossref_primary_10_1016_j_yebeh_2012_11_041
crossref_primary_10_1016_j_eplepsyres_2007_08_004
crossref_primary_10_1016_j_eplepsyres_2021_106829
crossref_primary_10_1177_15357597241253505
crossref_primary_10_1007_s40120_019_0137_0
crossref_primary_10_1097_NRL_0b013e31815c613d
crossref_primary_10_1177_15357597211015659
crossref_primary_10_3233_ADR_200286
crossref_primary_10_1007_s11065_007_9043_9
crossref_primary_10_1016_j_eplepsyres_2014_04_009
crossref_primary_10_1007_s13670_018_0235_3
crossref_primary_10_14581_jer_19003
crossref_primary_10_1016_j_eplepsyres_2008_03_022
crossref_primary_10_1016_j_neurol_2017_03_028
crossref_primary_10_1111_psyg_12463
crossref_primary_10_1007_s15014_014_0377_5
crossref_primary_10_1212_01_wnl_0000252941_50833_4a
crossref_primary_10_1016_j_mcna_2006_06_002
crossref_primary_10_1586_14737175_6_12_1801
crossref_primary_10_1111_j_1749_6632_2009_05113_x
crossref_primary_10_1016_j_seizure_2010_12_015
crossref_primary_10_1586_ern_10_170
crossref_primary_10_5698_1535_7511_11_1_9
crossref_primary_10_5698_1535_7511_13_1_22
crossref_primary_10_1111_j_1600_0404_2010_01464_x
crossref_primary_10_1007_s10309_021_00442_z
crossref_primary_10_1089_jpm_2006_9_24
crossref_primary_10_1007_s10309_013_0307_5
crossref_primary_10_1007_s00108_014_3467_0
crossref_primary_10_1007_s00415_013_7058_0
crossref_primary_10_1111_j_1600_0404_2006_00668_x
crossref_primary_10_1093_advances_nmz047
crossref_primary_10_3238_arztebl_2009_0135
crossref_primary_10_1007_s11940_022_00744_1
crossref_primary_10_1002_pds_5139
crossref_primary_10_1111_jgs_13807
crossref_primary_10_5698_1535_7511_12_5_184
crossref_primary_10_1212_WNL_0b013e3181cbcd5c
crossref_primary_10_1007_s13365_011_0074_x
crossref_primary_10_1016_j_eplepsyres_2006_03_004
crossref_primary_10_1212_01_wnl_0000316392_55784_57
crossref_primary_10_1016_j_yebeh_2009_02_030
crossref_primary_10_1080_14656566_2020_1843636
crossref_primary_10_1007_s11910_008_0049_3
crossref_primary_10_1007_s15016_012_0514_8
crossref_primary_10_1016_j_neuarg_2013_03_001
crossref_primary_10_1097_MLR_0000000000001072
crossref_primary_10_1177_2042098611411127
crossref_primary_10_1097_01_wco_0000218235_67840_82
crossref_primary_10_1136_pgmj_2009_082883
crossref_primary_10_1038_ncpneuro0557
crossref_primary_10_1093_nop_npu010
crossref_primary_10_1016_j_eplepsyres_2005_07_019
crossref_primary_10_1586_14737175_8_6_929
crossref_primary_10_1517_14740338_2015_1088001
crossref_primary_10_1016_j_ncl_2009_06_007
crossref_primary_10_1016_S0513_5117_08_70029_2
crossref_primary_10_1111_epi_16068
crossref_primary_10_1007_s10309_009_0042_0
crossref_primary_10_1155_2012_641323
crossref_primary_10_5698_1535_7511_15_5_255
crossref_primary_10_1007_s00115_009_2680_x
crossref_primary_10_1007_s11940_015_0342_9
crossref_primary_10_1080_14656566_2019_1618272
crossref_primary_10_1016_j_seizure_2017_02_006
crossref_primary_10_1016_j_ncl_2016_04_004
crossref_primary_10_1017_S0959259815000052
crossref_primary_10_1016_j_ncl_2006_01_001
crossref_primary_10_1517_14740338_2012_677026
crossref_primary_10_1177_15333175241303569
crossref_primary_10_3805_jjes_28_17
crossref_primary_10_5698_1535_7511_12_1_24
crossref_primary_10_1016_j_amjopharm_2007_06_001
crossref_primary_10_1016_j_amjopharm_2010_02_003
crossref_primary_10_1007_s11910_010_0120_8
crossref_primary_10_1212_WNL_0000000000200779
crossref_primary_10_1177_17562864211037430
crossref_primary_10_1111_epi_16616
crossref_primary_10_1016_j_yebeh_2009_01_005
crossref_primary_10_1016_j_seizure_2006_02_002
crossref_primary_10_1212_01_wnl_0000313157_15089_e6
crossref_primary_10_1016_j_yebeh_2011_04_005
crossref_primary_10_1111_j_1528_1167_2006_00585_x
crossref_primary_10_1177_1756285609351945
crossref_primary_10_1097_WNF_0000000000000174
crossref_primary_10_1212_01_CON_0000431382_06438_cd
crossref_primary_10_1007_s10309_008_0292_2
crossref_primary_10_1080_14656566_2020_1865311
crossref_primary_10_1186_s13256_023_03912_2
crossref_primary_10_1016_j_seizure_2008_06_003
crossref_primary_10_1111_epi_17494
crossref_primary_10_1080_14656566_2018_1549543
crossref_primary_10_1097_00132985_200605020_00012
crossref_primary_10_1111_j_1528_1167_2009_02235_x
crossref_primary_10_1016_j_yebeh_2010_07_016
crossref_primary_10_1111_epi_16721
crossref_primary_10_1345_aph_1P385
crossref_primary_10_12659_MSM_894365
crossref_primary_10_1002_npr2_12196
crossref_primary_10_1007_s00228_011_1051_2
crossref_primary_10_1111_epi_12926
crossref_primary_10_2165_00023210_200822110_00003
crossref_primary_10_1097_WCO_0b013e3282f827f9
ContentType Journal Article
CorporateAuthor VA Cooperative Study 428 Group
CorporateAuthor_xml – name: VA Cooperative Study 428 Group
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1212/01.WNL.0000167384.68207.3E
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1526-632X
ExternalDocumentID 15955935
Genre Research Support, U.S. Gov't, Non-P.H.S
Multicenter Study
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID ---
-~X
.55
.GJ
.XZ
.Z2
01R
0R~
123
1J1
1KJ
354
3PY
4Q1
4Q2
4Q3
53G
5RE
5VS
6PF
77Y
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AASXQ
AAWTL
AAXQO
AAYEP
AAYOK
ABBLC
ABIVO
ABJNI
ABOCM
ABVCZ
ACCJW
ACDDN
ACGFS
ACIJW
ACILI
ACLDA
ACOAL
ACWRI
ACXJB
ADGGA
ADNKB
AE6
AEBDS
AENEX
AFDTB
AFEXH
AFFNX
AFUWQ
AGINI
AHOMT
AHQNM
AHVBC
AIJEX
AJCLO
AKCTQ
AKULP
AKWKN
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BOYCO
BQLVK
BYPQX
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
E.X
EBS
ECM
EIF
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FW0
GQDEL
HZ~
H~9
IKYAY
IN~
J5H
JF7
KD2
KMI
L-C
L7B
N4W
N9A
NEJ
NPM
N~7
N~B
O9-
OAG
OAH
OBH
ODMTH
OHH
OHT
OHYEH
OJAPA
OL1
OLB
OLH
OLU
OLV
OLW
OLY
OLZ
OPX
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
RHI
RLZ
RXW
SJN
TEORI
V2I
VVN
VXZ
W3M
WH7
WOQ
WOW
X7M
XJT
XOL
XSW
XXN
XYM
XYN
YBU
YCJ
YFH
ZKB
~9M
ID FETCH-LOGICAL-c347t-7a0f4e8c804da8d280d587a4b867e178bf26f9659d85dd7f60f9e69c1c9eccdd2
IngestDate Wed Feb 19 01:41:43 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c347t-7a0f4e8c804da8d280d587a4b867e178bf26f9659d85dd7f60f9e69c1c9eccdd2
PMID 15955935
ParticipantIDs pubmed_primary_15955935
PublicationCentury 2000
PublicationDate 2005-06-14
PublicationDateYYYYMMDD 2005-06-14
PublicationDate_xml – month: 06
  year: 2005
  text: 2005-06-14
  day: 14
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Neurology
PublicationTitleAlternate Neurology
PublicationYear 2005
References 16477322 - Epilepsy Curr. 2006 Jan-Feb;6(1):27-9
16388556 - ACP J Club. 2006 Jan-Feb;144(1):6
15955930 - Neurology. 2005 Jun 14;64(11):1834-5
References_xml – reference: 16477322 - Epilepsy Curr. 2006 Jan-Feb;6(1):27-9
– reference: 15955930 - Neurology. 2005 Jun 14;64(11):1834-5
– reference: 16388556 - ACP J Club. 2006 Jan-Feb;144(1):6
SSID ssj0015279
Score 2.3844006
Snippet To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine...
SourceID pubmed
SourceType Index Database
StartPage 1868
SubjectTerms Aged
Aging - physiology
Amines - administration & dosage
Amines - adverse effects
Amines - blood
Anticonvulsants - administration & dosage
Anticonvulsants - adverse effects
Anticonvulsants - blood
Carbamazepine - administration & dosage
Carbamazepine - adverse effects
Carbamazepine - blood
Cerebral Infarction - complications
Cyclohexanecarboxylic Acids - administration & dosage
Cyclohexanecarboxylic Acids - adverse effects
Cyclohexanecarboxylic Acids - blood
Dose-Response Relationship, Drug
Double-Blind Method
Epilepsy - drug therapy
Epilepsy - epidemiology
Epilepsy - etiology
gamma-Aminobutyric Acid - administration & dosage
gamma-Aminobutyric Acid - adverse effects
gamma-Aminobutyric Acid - blood
Hospitals, Veterans - statistics & numerical data
Humans
Patient Compliance - statistics & numerical data
Patient Selection
Treatment Outcome
Triazines - administration & dosage
Triazines - adverse effects
Triazines - blood
United States
United States Department of Veterans Affairs - statistics & numerical data
Title New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine
URI https://www.ncbi.nlm.nih.gov/pubmed/15955935
Volume 64
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6rgngR32_JwZt27XaTJvUmooioiCh6UtI8Fg-7LW5B3F_vJGm3XVFRL6U0u2nJfJlMJjPfILRHKSMqYWkASwENSBRpuEt1EEZCS2vCGpf1fnUdn9-Ti0f62Gq9NbNLirQtR1_mlfxHqvAM5GqzZP8g2XGn8ADuQb5wBQnD9VcytsGJNhq62O_Z11my_X2dwzzPh-8-ixlWIpX1X0ZgVg4r-uieSEVug4ScwgFEZIWrjqWrSE5pzyD6YgRdDSYihRyTR9MNf5u9eQfqcX28dCv6Q-FF10hzcNzfHjN1MPHN67v3FpxNOB-oDZLySZ9tXSrMKA7iriuJPtaonpe8Qk6noR8tOf-XihtWUJeM0H64vnSckh1bjpS0Y25dYN3T5p9gAPO-EynYYgAnz3fyc-snUu2qaQpNwfbC1ku1Tp7y8IlGLCn5aeGzDr__KFfTyXf0aVfirJO7BTRfbivwscfIImrpwRKavSoDJ5bRE0AFO6jgMVRwBZUjLHANFOyAgjODa6Ac4AZMDjD8Fk-AZAXdn53enZwHZWmNQHYJKwImQkM0lzwkSnAV8VBRzgRJecx0h_HURLGxXJOKU6WYiUOT6DiRHZnAnFcqWkXTg2yg1xGmSjKjFVh6whAjiaBgRHOwIrmBRd2IDbTmR-Y59_wpz9WYbX7bsoXmarRtoxkDE1bvgPVXpLtOVh-KH1a3
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+onset+geriatric+epilepsy%3A+a+randomized+study+of+gabapentin%2C+lamotrigine%2C+and+carbamazepine&rft.jtitle=Neurology&rft.au=Rowan%2C+A+J&rft.au=Ramsay%2C+R+E&rft.au=Collins%2C+J+F&rft.au=Pryor%2C+F&rft.date=2005-06-14&rft.eissn=1526-632X&rft.volume=64&rft.issue=11&rft.spage=1868&rft_id=info:doi/10.1212%2F01.WNL.0000167384.68207.3E&rft_id=info%3Apmid%2F15955935&rft_id=info%3Apmid%2F15955935&rft.externalDocID=15955935